Yahoo Finance • 5 months ago
Veru Inc. MIAMI, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology and viral-induced acute r... Full story
Yahoo Finance • 7 months ago
-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function... Full story
Yahoo Finance • 8 months ago
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ARDS including the “tripledemic viruses”: Influenza, RSV, and SAR... Full story
Yahoo Finance • 8 months ago
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress s... Full story
Yahoo Finance • 9 months ago
MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndro... Full story
Yahoo Finance • a year ago
Research grants from U.S. Department of Defense (DoD) and National Cancer Institute’s Research Project Grant (NCI R01) awarded to UTHSC to study new types of targeting agents for multiple cancer indications with significant unmet need Agg... Full story
Yahoo Finance • a year ago
Agreement reached with FDA on confirmatory Phase 3 clinical trial design for sabizabulin treatment of hospitalized COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS), including two planned interim efficacy... Full story
Yahoo Finance • a year ago
Reached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality at Day 60 Study to expand treatment population to include all WHO-4, WHO-5, and WHO-6 hospitalized adult... Full story
Yahoo Finance • a year ago
MIAMI, FL, May 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-relate... Full story
Yahoo Finance • a year ago
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases that has a commercial sexual heal... Full story
Yahoo Finance • a year ago
Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress syndrome (ARDS) Company plans pre-Invest... Full story
Yahoo Finance • a year ago
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Generac Holdings Inc. (NYSE: GNRC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with alleged materiall... Full story
Yahoo Finance • a year ago
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that it is investigating whether the directors and/or officers of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU) breached their fiduciary duties of loy... Full story
Yahoo Finance • a year ago
MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that Mitchell... Full story
Yahoo Finance • a year ago
Share of Veru Inc. (VERU) plunged 31.0% toward a 2 1/2-year low in premarket Friday, after the U.S. Food and Drug Administration turned down the biopharmaceutical company’s request for Emergency Use Authorization (EUA) for sabizabulin, its... Full story
Yahoo Finance • a year ago
MIAMI, FL, March 02, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that the U.S.... Full story
Yahoo Finance • a year ago
SAN DIEGO, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Generac Holdings Inc.(NYSE: GNRC) Johnson Fistel, LLP is investigating potential claims on behalf Generac Holdings Inc. (NYSE: GNRC) against certain of its officers and directors. If you... Full story
Yahoo Finance • a year ago
SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Veru Inc. (NASDAQ: VERU). Investors who purchased shares of Veru Inc. (NASDAQ: VERU) p... Full story
Yahoo Finance • a year ago
LOS ANGELES, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story
Yahoo Finance • a year ago
SAN FRANCISCO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now. Class Period: May 11, 2022 – Nov. 9, 2022 Lead Plaintiff Deadline: Feb. 6, 2023... Full story
Home
Money Search
Trending Sports
Gallery
Shop
Blog
Examples
Data & Glossary
Elements of Bball
Harden Maze
About
